IL97311A0 - Vectors and compounds for expression of glycosylation mutants of human protein c - Google Patents

Vectors and compounds for expression of glycosylation mutants of human protein c

Info

Publication number
IL97311A0
IL97311A0 IL97311A IL9731191A IL97311A0 IL 97311 A0 IL97311 A0 IL 97311A0 IL 97311 A IL97311 A IL 97311A IL 9731191 A IL9731191 A IL 9731191A IL 97311 A0 IL97311 A0 IL 97311A0
Authority
IL
Israel
Prior art keywords
vectors
human protein
compounds
expression
glycosylation mutants
Prior art date
Application number
IL97311A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL97311A0 publication Critical patent/IL97311A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Eye Examination Apparatus (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
IL97311A 1990-02-23 1991-02-20 Vectors and compounds for expression of glycosylation mutants of human protein c IL97311A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48408190A 1990-02-23 1990-02-23
US62806390A 1990-12-21 1990-12-21

Publications (1)

Publication Number Publication Date
IL97311A0 true IL97311A0 (en) 1992-05-25

Family

ID=27047851

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97311A IL97311A0 (en) 1990-02-23 1991-02-20 Vectors and compounds for expression of glycosylation mutants of human protein c

Country Status (19)

Country Link
US (1) US5460953A (fr)
EP (1) EP0443874B1 (fr)
JP (1) JP3004375B2 (fr)
KR (1) KR910021477A (fr)
CN (1) CN1055560A (fr)
AT (1) ATE153069T1 (fr)
AU (1) AU645776B2 (fr)
CA (1) CA2036894C (fr)
DE (1) DE69126049T2 (fr)
DK (1) DK0443874T3 (fr)
ES (1) ES2101716T3 (fr)
FI (1) FI910854L (fr)
GR (1) GR3023756T3 (fr)
IE (1) IE910611A1 (fr)
IL (1) IL97311A0 (fr)
NO (1) NO910719L (fr)
NZ (1) NZ237199A (fr)
PT (1) PT96853A (fr)
YU (1) YU31891A (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
SE9701228D0 (sv) * 1997-04-03 1997-04-03 Bjoern Dahlbaeck Rekombinanta protein-C-och protein-S-varianter
US7081519B1 (en) 1997-04-24 2006-07-25 Zymogenetics, Inc. Antibodies to serine protease polypeptides
US6153420A (en) * 1997-04-24 2000-11-28 Zymogenetics, Inc. Serine protease polypeptides and materials and methods for making them
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
EP1255821B1 (fr) 2000-02-02 2004-12-29 Eli Lilly And Company Derives de proteine c
CA2400187A1 (fr) * 2000-02-11 2001-08-16 Eli Lilly And Company Derives de la proteine c
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002210388B2 (en) * 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
WO2006044294A2 (fr) * 2004-10-14 2006-04-27 Eli Lilly And Company Analogues de la proteine humaine c
US7655428B2 (en) * 2005-12-22 2010-02-02 Biosite, Inc. Latent protein C assays and their uses for diagnosis and/or prognosis in systemic inflammatory response syndromes
CA2654761A1 (fr) * 2006-06-09 2007-12-13 The University Of British Columbia Polymorphismes de l'interferon gamma utilises comme indicateurs de resultat chez des sujets gravement malades
WO2008048646A1 (fr) * 2006-10-18 2008-04-24 Socratech L.L.C. Utilisation de la protéine c humaine présentant un état de glycosylation et une teneur en acide sialique modifiés en tant que médicament
CA2712057A1 (fr) * 2008-01-15 2009-07-23 The University Of British Columbia Proteine c rs2069915 en tant que predicteur de reponse de survie et administration de proteine c ou d'un compose de type proteine c active
EP2539448B1 (fr) * 2010-02-26 2016-12-14 The Children's Hospital of Philadelphia Zymogène de la protéine c et ses procédés d'utilisation pour prévenir les métastases cancéreuses
WO2012068519A2 (fr) 2010-11-19 2012-05-24 Sirius Genomics Inc. Marqueurs associés à la réponse à une administration de la protéine c activée, et leurs utilisations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
EP0215548B2 (fr) * 1985-06-27 1998-01-07 Zymogenetics, Inc. Expression de protéine C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
US4935349A (en) * 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
DE3789664T3 (de) * 1986-01-31 2004-09-16 Genetics Institute, LLC, Cambridge Neue thrombolytische proteine.
US5135854A (en) * 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C

Also Published As

Publication number Publication date
FI910854A7 (fi) 1991-08-24
NO910719D0 (no) 1991-02-22
CA2036894C (fr) 2002-01-15
NZ237199A (en) 1993-04-28
FI910854A0 (fi) 1991-02-22
DK0443874T3 (da) 1997-11-17
IE910611A1 (en) 1991-08-28
CA2036894A1 (fr) 1991-08-24
FI910854L (fi) 1991-08-24
EP0443874A3 (en) 1991-10-16
EP0443874A2 (fr) 1991-08-28
GR3023756T3 (en) 1997-09-30
YU31891A (sh) 1994-06-10
ATE153069T1 (de) 1997-05-15
ES2101716T3 (es) 1997-07-16
PT96853A (pt) 1991-10-31
DE69126049T2 (de) 1997-09-25
AU645776B2 (en) 1994-01-27
KR910021477A (ko) 1991-12-20
NO910719L (no) 1991-08-26
EP0443874B1 (fr) 1997-05-14
JPH04211380A (ja) 1992-08-03
US5460953A (en) 1995-10-24
DE69126049D1 (de) 1997-06-19
JP3004375B2 (ja) 2000-01-31
CN1055560A (zh) 1991-10-23
AU7130791A (en) 1991-08-29

Similar Documents

Publication Publication Date Title
EP0443874A3 (en) Vectors and compounds for expression of glycosylation mutants of human protein c
HUT69615A (en) Protein c d
YU86883A (en) Process for producing functional human urochinase proteins
EP0379556A4 (en) Production of glucose oxidase in recombinant systems
CA2053864A1 (fr) Formes modifiees d'hormones de reproduction
EP0327377A3 (en) Kex2 endoprotease and process for production thereof
CA2140531A1 (fr) Methode pour augmenter l'expression de proteines virales
HUT43108A (en) Process for producing new human tissue-type polypeptides of plazminogene activator activity
CA2015769A1 (fr) Production de polypeptides ayant une activite biologique par traitement avec une sequence de peptides exogene
HUT43111A (en) Process for producing human lizozime
ES2057183T3 (es) Procedimiento para la obtencion de lisozima humano.
NZ224243A (en) Single chain urokinase type plasminogen activator with yeast type glycosylation and site directed mutants thereof
IE870239L (en) Recombinant interleukin-2-composition
HUT53125A (en) Process for producing peptides with anticoagulant activity
ZA932830B (en) A novel anti-neoplastic cytokine
IL77152A0 (en) Expression vectors for protein production in e.coli and their production